ArticleJournal of gastrointestinal oncology2022

Study on efficacy and safety of transcatheter arterial chemoembolization (TACE) combined with regorafenib and PD-1 antibody versus continued TACE combined with regorafenib in patients with hepatocellular carcinoma after failed second-line treatment with regorafenib.

Haochen Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.